Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 37, 2013, Pages 15127-15132

  Eliasof, Scott ^a   Lazarus, Douglas ^a   Peters, Christian G ^a   Case, Roy I ^a   Cole, Roderic O ^a   Hwang, Jungyeon ^a   Schluep, Thomas ^b   Chao, Joseph ^c   Lin, James ^c   Yen, Yun ^c   Han, Han ^d   Wiley, Devin T ^d   Zuckerman, Jonathan E ^d   Davis, Mark E ^d  

^a Cerulean Pharma Inc   (United States)

^b Calando Pharmaceuticals   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d California Institute of Technology   (United States)

Author keywords

Clinical translation; Interspecies scaling; Nanomedicine; Nanoparticles; Pharmacodynamics

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CRLX 101; POLYMER; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG URINE LEVEL; HUMAN; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; SOLID TUMOR; TUMOR XENOGRAFT;

CLINICAL TRANSLATION; INTERSPECIES SCALING; NANOMEDICINE; NANOPARTICLES; PHARMACODYNAMICS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; CYCLODEXTRINS; DOGS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; NANOCONJUGATES; RATS; STOMACH NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84883789058     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1309566110     Document Type: Article

References (39)

1. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771-782.
2. Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9(8):615-627.
3. Shi J, Xiao Z, Kamaly N, Farokhzad OC (2011) Self-assembled targeted nanoparticles: Evolution of technologies and bench to bedside translation. Acc Chem Res 44(10): 1123-1134.
4. Sheridan C (2012) Proof of concept for next-generation nanoparticle drugs in humans. Nat Biotechnol 30(6):471-473.
5. Bourzac K (2012) Nanotechnology: Carrying drugs. Nature 491(7425):S58-S60.
6. Bouchie A (2012) Companies in footrace to deliver RNAi. Nat Biotechnol 30(12):1154-1157.
7. Weiss GJ, et al. (2013) First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 31(4):986-1000.
8. Hrkach J, et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra39.
9. Davis ME, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070.
10. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science 338(6109):903-910.
11. Oerlemans C, et al. (2010) Polymeric micelles in anticancer therapy: Targeting, imaging and triggered release. Pharm Res 27(12):2569-2589.
12. Davis ME (2009) Design and development of IT-101, a cyclodextrin- containing polymer conjugate of camptothecin. Adv Drug Deliv Rev 61(13):1189-1192.
13. Schluep T, et al. (2009) Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci USA 106(27):11394-11399.
14. Schluep T, Cheng J, Khin KT, Davis ME (2006) Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 57(5):654-662. (Pubitemid 43237851)
15. Gaur S, et al. (2012) Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 8(5):721-730.
16. Numbenjapon T, et al. (2009) Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res 15(13): 4365-4373.
17. Schluep T, et al. (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT- 101 in multiple cancer models. Clin Cancer Res 12(5):1606-1614.
18. Cheng J, Khin KT, Jensen GS, Liu A, Davis ME (2003) Synthesis of linear, beta-cyclodextrinbased polymers and their camptothecin conjugates. Bioconjug Chem 14(5):1007-1017. (Pubitemid 37152961)
19. Mi Z, Burke TG (1994) Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study. Biochemistry 33(42):12540-12545. (Pubitemid 24345883)
20. Li B, et al. (2005) Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70(11):1673-1684. (Pubitemid 41540360)
21. Cabral H, et al. (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6(12):815-823.
22. Xiao K, et al. (2011) The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32(13):3435-3446.
23. Szebeni J, et al. (2002) Role of complement activation in hypersensitivity reactions to Doxil and Hynic PEG liposomes: Experimental and clinical studies. J Liposome Res 12(1-2):165-172. (Pubitemid 34846969)
24. Uziely B, et al. (1995) Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13(7):1777-1785.
25. Gabizon A, et al. (2008) An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 61(4):695-702.
26. Song G, Wu H, Yoshino K, Zamboni WC (2012) Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 22(3):177-192.
27. Caron WP, Song G, Kumar P, Rawal S, Zamboni WC (2012) Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther 91(5):802-812.
28. Hamaguchi T, et al. (2010) Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 16(20):5058-5066.
29. Lim WT, et al. (2010) Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 21(2):382-388.
30. Burke TG, Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37(1):40-46. (Pubitemid 24058811)
31. Kurono Y, Miyajima M, Ikeda K (1993) [Interaction of camptothecin derivatives with human plasma proteins in vitro.]. Yakugaku Zasshi 113(2):167-175, Japanese.
32. Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL (1998) Camptothecin delivery systems: Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol 42(5):407-414. (Pubitemid 28430372)
33. Rowinsky EK, et al. (2003) A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 21(1):148-157.
34. Posey JA, 3rd, et al. (2005) Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res 11(21):7866-7871.
35. Schoemaker NE, et al. (2002) A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 87(6):608-614.
36. Wachters FM, et al. (2004) A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer 90(12):2261-2267. (Pubitemid 38961887)
37. Koizumi F, et al. (2006) Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66(20):10048-10056. (Pubitemid 44672058)
38. Sapra P, et al. (2008) Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 14(6):1888-1896. (Pubitemid 351469476)
39. Kurzrock R, et al. (2012) Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 118(24):6144-6151.